RecruitingNCT04772963

Genetics of Central Nervous System Arteriovenous Malformations (GENE-MAV)

Genetics of Central Nervous System Arteriovenous Malformations (AVM): Genotype-Phenotype Correlation and Prognostic Impact on Patients With AVM


Sponsor

Fondation Ophtalmologique Adolphe de Rothschild

Enrollment

300 participants

Start Date

Feb 17, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

Cerebral and medullary arteriovenous malformations (AVMs) lead to arterial and venous networks to communicate pathologically, creating an arteriovenous shunt. The occurrence of intracranial haemorrhage is the most important prognostic factor of AVMs because it is associated with a significant morbidity and mortality. The genetic, molecular and cellular mechanisms that cause vascular malformations of the central nervous system are partially known and the influence of genetic damage on the prognosis of AVMs is poorly known.


Eligibility

Inclusion Criteria1

  • Patient with a vascular malformation of the cerebral or medullary identified on diagnostic imaging (angio-CT, angio-MRI or diagnostic angiography) for which clinical monitoring alone or intervention (endovascular treatment, surgery or radiosurgery) is planned in the centres participating in the research.

Exclusion Criteria1

  • Pregnant, parturient or breastfeeding woman

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

GENETICblood sample

During the arteriography a peripheral venous sampling


Locations(1)

HOPITAL FONDATION Adolphe de ROTHSCHILD

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04772963


Related Trials